FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

Investigation Questions Drug's Approval for Agitation in AD

REXULTI® (brexpiprazole) Agitation associated with dementia due to Alzheimer's disease

REXULTI® (brexpiprazole), Agitation associated with dementia due to Alzheimer's disease

FDA approves treatment for agitation associated with dementia created by Princeton-based Otsuka

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

FDA approves first drug to treat agitation associated with dementia due to Alzheimer's

Researcher finds help for Alzheimer's-associated agitation with new FDA- approved treatment

Otsuka and Lundbeck Announce REXULTI for Alzheimer's Agitation

Medicare coverage debates amplify as FDA approves Rexulti for Alzheimer's agitation

Important News for Older Adults: FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease - Alliance for Aging Research